Topical foam formulations for pharmaceuticals and cosmetics at FOAMIX. Pharmaceutical foam drug formulations

Foamix to present at the UBS 2010 Global Specialty Pharmaceuticals Conference

New U.S. Patent Grant to Foamix for its Hygroscopic and Waterless Breakable Foam Technology

Foamix Receives a New U.S. Patent for its Emollient and Aqueous Foam Technology

Foamix is Granted a Fourth U.S. Patent for OilGel™, Directed to Pharmaceutical Compositions and their Dermatological, Gynecological and Ophthalmic Applications

Foamix Ltd. and Therapeutics Inc. Enter into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases

US Grant for Foamix's Saccharide Foam Patent - Topical "Sweet Foam" Products for Wound & Burn Therapy

Foamix is a Finalist for the Red Herring 100 Global Award for Most Promising Technology Ventures

Dermatology co Foamix teams with Switzerland's Galderma

Foamix Expands International Patent Protection for its Emollient Foam Platform

Foamix Extends Collaboration with Galderma

Foamix Ltd. and VIB Sign Co-Development Agreement for Innovative Topical Therapy for Psoriasis

Promius Pharma, LLC Launches Scytera™ (Coal Tar) Foam 2% for Treatment of Psoriasis

Foamix is Finalist for International 2008 SCRIP Award

Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis

Omnibus Survey:72% of Women Are Dissatisfied with Their Current Treament of Vaginal Infection

Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases

Foamix is a finalist for the Red Herring 100 Europe 2008 Award

BIRD invests $14m in 16 joint projects; English Hebrew

Foamix Announces New Foam Patent Approvals

Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis

Foamix Acquires Rights to Dual Chamber Aerosol Foam Technology

In-Pharma Technologist.com: Best Foam Forward

Foamix presents Innovative Intra-Vaginal Foam Delivery for Gynecology

Foamix Signs R&D Collaboration and License Agreement with Dr. Reddy’s for the Development and Commercialization of Psoriasis Foam

YNET: Collaboration with Warner Chilcott on gynecologic treatment (article in Hebrew)

Warner Chilcott and Foamix Collaborate on Gynecologic Foam Product

Foamix and Intendis Sign License Agreement for the Development of a Dermatological Foam

Globes: Foamix collaborates with Warner Chilcott on acne treatment

Warner Chilcott and Foamix Collaborate on Foam Product for the Treatment of Acne

Welcome to Foamix

Foamix Ltd is a dynamic and growing drug development company, specializing in dermatologic and other topical products.

Foamix is engaged in the development of five technology platforms:

DermaFoamix™, Innovative Emollient, alcohol-free, emulsion-based foam formulations of drugs for the treatment of skin disorders.
GyneFoamix™, Proprietary foam formulations of gynecological drugs
Suspension Foam™, unique foams comprising insoluble drugs and cosmetic agents.
BabyFoamix™, Foam formulations for the prevention and treatment of diaper rash and delicate baby skin care foams.
CosmetoFoamix™, Creative cosmetic foam formulations, for elegant and effective derma-cosmetic treatment of body and facial skin.
OILGEL™, providing oil-gel formulations, which replace the need to use ointments for the effective topical delivery of oil soluble drugs.

While developing our own products, we cooperate with pharmaceutical companies in developing DermaFoamix™, GyneFoamix™, BabyFoamix™, CosmetoFoamix™ and OILGEL™ products, containing their specific drugs and cosmetic active agents. We have pursued this approach in several cases, to the full satisfaction of our partners.

We invite you to learn about our unique technology platforms and understand their benefits to your projects by exploring our web site. Please feel free to contact us if you would like more information.